Law360, New York (August 21, 2007, 12:00 AM EDT) -- A drug wholesaler has sought treble damages in a putative class action lawsuit against Sanofi-Aventis, accusing the French pharmaceutical giant of unlawfully blocking generic competition for Sanofi's rheumatoid arthritis treatment Arava by filing a sham Citizen Petition with the U.S. Food and Drug Administration.
Louisiana Wholesale Drug Co. Inc. filed the lawsuit on Friday in federal court in Manhattan, against Sanofi-Aventis, Sanofi-Aventis US LLC and Aventis Pharmaceuticals Inc.
The drug at issue in the suit is leflunomide, which is sold under the brand name Arava. AB-rated...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.